Mumbai-based pharma major Lupin Ltd has acquired Dutch firm Nanomi B.V. for an undisclosed amount, as per a stock market disclosure. With this acquisition, Lupin has made its foray into the technology intensive complex injectables space.
“With the use of Nanomi’s proprietary technology platform, Lupin would be able to make significant in-roads into the niche area of complex injectables,” said Vinita Gupta, CEO of Lupin.
Founded in 2004, Netherlands-based Nanomi provides drug delivery solutions and develops pharmaceutical products based on nano and micro particles. It has patented technology platforms to develop complex injectable products.
The firm targets business-to-business partnerships with pharma and biotech companies and has entered into multiple business agreements with companies in related fields.
Established in 1968 by Desh Bandhu Gupta, Lupin is the manufacturer of anti TB drugs and started selling branded products in the US in 2004 after acquiring the Suprax antibiotic from Wyeth. It is the third-largest Indian pharmaceutical company by revenues.
This deal marks the first inorganic expansion move by Lupin in almost three years.
(Edited by Joby Puthuparampil Johnson)